Rubicon Research earnings calls.

Rubicon Research delivered an exceptional Q3 FY26 with 52% YoY revenue growthCurrent reported value: 52% YoY revenue growth. No comparable prior figure is available in the source record. to Rs 476Current reported value: 476. No comparable prior figure is available in the source record. crore, driven by broad-based launches and market share gains across both specialty and generic portfolios. PAT surged 91% YoYCurrent reported value: PAT surged 91% YoY. No comparable prior figure is available in the source record. to Rs 73Current reported value: 73. No comparable prior figure is available in the source record. crore, reflecting strong operating leverage. The 98% USD-revenue exposure ensures healthy dollar-denominated growth. Key concern is gross margin pressure from higher-than-anticipated outsourcing (demand has exceeded internal capacity), though management reaffirmed confidence in 22-23% operating EBITDA marginCurrent reported value: 22-23% operating EBITDA margin. No comparable prior figure is available in the source record. guidance. The Pithampur facility remains on track for mid-2026 operationalization and Q1 CY27 commercialization, which should restore gross margins to 67-68% range as in-house manufacturing scales. R&D spend at 10.8% YTD aligns with 10-11% guidance, with management projecting R&D productivity above 5x multiplier for future periods. Specialty portfolio's gross profit contribution has risen to 31-32%Current 31-32%. Reported change: +420-520bps YoY. from 26.9% in FY25, improving portfolio quality. Risk includes near-term GM headwinds from outsourcing and execution risk on Pithampur ramp-up timeline.